Seaside Therapeutics Initiates Phase 2b Study Of STX209 In Autism Spectrum Disorders

Friday, Aug. 5th 2011 6:40 AM

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 (arbaclofen) on social impairment in children, adolescents and adults (ages 5 to 21) with autism spectrum disorders (ASD). The Company announced positive results from an open-label Phase 2a study of STX209 in September of 2010.

VN:F [1.9.22_1171]
Rating: 5.0/5 (2 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
Seaside Therapeutics Initiates Phase 2b Study Of STX209 In Autism Spectrum Disorders, 5.0 out of 5 based on 2 ratings
Posted on Friday, Aug. 5th 2011 6:40 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply